CAR-T細胞療法の世界市場（2022年）：市場規模、予測、臨床試験、動向（2022年2月発行）

2012年当時、CAR-Tの臨床試験数はわずか12件でしたが、現在では1,200件以上にまで急増しています。臨床パイプラインにあるCAR-T製品に基づくと、承認されたCAR-T細胞療法の件数は今後5年以内に2桁に達し、2035年には100件を超えると予測されています。

CAR-Tの資金調達は驚異的な新水準に達しており、急速に拡大する再生医療分野に参入しようとする投資家がCAR-Tの新興企業に多額の資金を提供し、流れが大きくなっています。近年、CAR-T企業の時価総額は1,000億米ドルという驚異的な額になっています。

当レポートでは、世界のCAR-T細胞療法市場について調査し、市場規模や予測、製品・適応症・地域別の市場分析、臨床試験活動、特許分析、市場動向、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

第2章 CAR-T細胞療法：技術開発

• CAR-T細胞
• CAR-T細胞発達の進化
• 血液がん細胞に存在する抗原
• T細胞に受容体遺伝子を挿入するためのツール
• T細胞のCAR-T細胞への形質転換
• フィニッシュラインを越える5つのCAR-T療法
• CAR-T療法に関連する毒性
• CAR-T細胞療法の未来
• CAR-T療法のメリット
• CAR-T療法のデメリット
• 2021年以降のCAR-T療法の拡大

第3章 CAR-T細胞療法：製品開発

• CAR-T療法製品の現状
• 将来のCAR-T製品候補
• CAR-T療法の変革の可能性
• 少数の患者集団と巨大な臨床試験の情勢

第4章 CAR-T細胞の製造

• CAR-T製造における自動化
• 自家CAR-T製造における運営費
• 同種異系CAR-T製造における稼働費

第5章 CAR-T標的抗原：簡単な概要

第6章 CAR-T特許の情勢

• CAR-T特許出願の地理的起源
• 主要CAR-T特許管轄10区域
• CAR-T細胞特許出願人の所属

第7章 世界のCAR-T臨床試験：概要

第8章 出版された科学論文とNIH助成金

• 発表論文数
• CAR-T調査のためのNIH資金

第9章 CAR-T療法スペースでの取引

• 最新のCAR-T取引
  • Dr. Reddy's Laboratories/Shenzhen Pregene Biopharma
  • Abbvie/Caribou Biosciences
  • Gilead/Tango Therapeutics
  • Kite/Teneobio
  • Fate/Janssen
  • Juno/Oxford Biomedica
  • Allogene/MaxCyte
  • Applied DNA Sciences, Inc.
  • Cellectis/Servier
  • Cell Therapies, Pvt. Ltd
  • Astellas/Adaptimmune
  • Astellas/Xyphos
  • Carisma Therapeutics, Inc./NYU Langone Health

第10章 市販のCAR-T製品

• Kymriah (Tisagenlecleucel)
• Yescarta（Axicabtagene ciloleucel）
• Tecartus（Brexucabtagene autoleucel）
• Breyanzi（Lisocabtagene maraleucel）
• Abecma（Idecabtagene vicleucel/Ide-Cel）
• その他の有望なCAR-T製品候補
  • ALLO-501
  • CTX110
  • UCART19
  • AUTO1
  • JCARH125
  • LCAR-B38M
  • PBCAR20A
  • UCART123
  • PRGN-3006
  • UCART22
  • UCARTCS1

第11章 CAR-T療法の償還

• CAR-T療法に対する米国の病院の償還
• EU5ヵ国におけるCAR-T療法の結果に基づく償還
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第12章 血液がん：技術と治療

• リンパ腫
  • ホジキンリンパ腫（HL）
  • 非ホジキンリンパ腫（NHL）
• 白血病
  • 白血病の種類
• 多発性骨髄腫（MM）
• 血液がんの治療法の選択肢
  • 化学療法
  • 放射線治療
  • 標的療法
  • 幹細胞移植
  • 免疫療法
• がん治療の驚異的なコスト

第13章 CAR-T細胞療法の市場分析

• 製品別：CAR-T細胞療法の世界市場
• 地域別：CAR-T療法の世界市場
• 適応症別：CAR-T療法の世界市場
• CAR-T市場最前線にいる企業
• CAR-T2.0マーケットプレイスで成功するための障壁と戦略
  • CAR-T2.0の商業的成功への障壁
  • CAR-T2.0の市場開発戦略

第14章 CAR-T企業のプロファイル

• Aleta BioTherapeutics
• Allogene Therapeutics
• Anixa Biosciences, Inc.
• Arcellx, Inc.
• Atara Biotherapeutics
• Autolus Therapeutics, plc
• Bellicum Pharmaceuticals, Inc.
• BioNTech
• bluebird bio
• Cabaletta Bio
• Carina Biotech
• CARsgen Therapeutics
• Cartesian Therapeutics, Inc.
• CARTherics
• Celgene Corporation
• Cellectis
• Celularity, Inc.
• Celyad Oncology
• Creative Biolabs
• CRISPR Therapeutics
• CytoSeek
• Cytovia Therapeutics
• DiaCarta, Inc.
• Empirica Therapeutics
• Eureka Therapeutics, Inc.
• EXUMA Biotech Corp.
• Fate Therapeutics, Inc.
• Formula Pharmaceuticals, Inc.
• GEMoaB
• Gilead Sciences, Inc.
• Gracell Biotechnologies
• iCell Gene Therapeutics
• Janssen Biotech, Inc.
• Juno Therapeutics
• JW Therapeutics, Co., Ltd.
• Kite Pharma, Inc.
• Kyverna Therapeutics
• Lyell Immunopharma, Inc.
• MaxCyte, Inc.
• Minerva Biotechnologies Corporation
• Mnemo Therapeutics
• Mustang Bio, Inc.
• Nanjing Legend Biotechnology Co., Ltd.
• Noile-Immune Biotech
• Novartis International, AG
• Oxford Biomedica plc
• PeproMene Bio, Inc.
• Poseida Therapeutics, Inc.
• Precigen, Inc.
• Precision Biosciences
• Prescient Therapeutics
• ProMab Biotechnologies, Inc.
• Protheragen
• Sorrento Therapeutics, Inc.
• Synthekine
• TC Biopharm
• T-CURX
• Tessa Therapeutics, Pvt. Ltd.
• Tmunity Therapeutics, Inc.
• Wugen
• Xyphos Biosciences, Inc.
• Ziopharm Oncology, Inc.

付録

• 付録1：米国でCAR-T療法を提供する医療センター

LIST OF FIGURES

• Figure 2.1: The Structure of a T Cell
• Figure 2.2: The Binding of T Cells onto an Infected Cell
• Figure 2.3: Components of a CAR-T Cell
• Figure 2.4: The Three Domains of a CAR
• Figure 2.5: First Generation CARs
• Figure 2.6: Second Generation CARs
• Figure 2.7: Third Generation CARs
• Figure 2.8: Fourth Generation CARs
• Figure 2.9: Flow Chart Showing the Process of Manufacture of CAR-T Cells
• Figure 2.10: Diagrammatic Illustration of Autologous CAR-T
• Figure 2.11: Diagrammatic Illustration of Allogeneic CAR-T
• Figure 4.1: Leukopheresis and T Cell Isolation
• Figure 4.2: T Cell Culture and Transduction
• Figure 4.3: The Workflow in an Automated Manufacturing Unit
• Figure 4.4: Operating Expenses in Autologous CAR-T Manufacturing
• Figure 4.5: Operating Expenses in Allogeneic CAR-T Manufacturing
• Figure 5.1: The CAR-T Target Distribution in Global Clinical Trials
• Figure 6.1: CAR-T-Related Patent Publications
• Figure 6.2: Granted CAR-T-Related Patents
• Figure 6.3: Geographical Origin of CAR-T Patent Applications
• Figure 6.4: Top Ten CAR-T Patent Jurisdictions
• Figure 6.5: Affiliations of CAR-T Cell Patent Applicants
• Figure 7.1: Percent Share of CAR-T Clinical Trials by Phase
• Figure 7.2: CAR-T Targeted Biomarkers in other Countries
• Figure 7.3: Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials
• Figure 7.4: CAR-T Clinical Trials Phase Summary, U.S. vs. China
• Figure 7.5: Geographic Distribution of CAR-T Clinical Trials
• Figure 7.6: Distribution of CAR-T Clinical Trials by Type of CAR Generations
• Figure 7.7: Distribution of CAR-T Clinical Trials by Type of ScFv Used
• Figure 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used
• Figure 8.1: Number of CAR-T-Related Published Papers in PubMed.gov
• Figure 10.1: Sales Revenues for Kymriah, 2018- Q2 2021
• Figure 10.2: Sales Revenues for Yescarta, 2018-Q2 2021
• Figure 10.3: Sales Data for Kymriah and Yescarta, Q1 of 2018 to Q2 of 2020
• Figure 12.1: Global Incidence of Blood Cancers in 2020
• Figure 12.2: Rate of Incidence and Death for Hodgkin Lymphoma in the U.S.
• Figure 12.3: Rate of New NHL Cases in the U.S.
• Figure 12.4: Rate of New DLBCL Cases in the U.S.
• Figure 12.5: Rate of New FL Cases in the U.S.
• Figure 12.6: Rate of New Leukemia Cases in the U.S.
• Figure 12.7: Distribution of New Leukemia Cases in the U.S. by Type
• Figure 12.8: Rate of New AML Cases in the U.S.
• Figure 12.9: Rate of New ALL Cases in the U.S.
• Figure 12.10: Rate of New CML Cases in the U.S.
• Figure 12.11: Rate of New CLL Cases in the U.S.
• Figure 12.12: Rate of New MM Cases in the U.S.
• Figure 13.1: Estimated Global Market for CAR-T Therapy by Products, 2021-2028
• Figure 13.2: Global Market for CAR-T Therapy by Geography, 2021-2028
• Figure 13.3: Global Market for CAR-T Therapy by Indication, 2021-2028
• Figure 14.1: Illustration of a Dual CAR

LIST OF TABLES

• Table 2.1: Potential CAR-Targeted Antigens Present on Hematological Malignancies
• Table 2.2: The Three CAR-T Therapies Crossing the Finishing Line: An Overview
• Table 2.3: Toxicities Associated with CAR-T Treatment
• Table 2.4: Strategies to Improve the Safety and Efficacy of CAR-T Therapy
• Table 2.5: New Target Antigens and New Target Cancers
• Table 2.6: A Partial List of Allogeneic CAR-T Companies
• Table 3.1: History of Development of CAR-T Cells
• Table 3.2: Approved CAR-T Products and Indications
• Table 3.3: The Next-Wave of CAR-T Approvals
• Table 3.4: Increased CAR-T Activity
• Table 3.5: Very Small Patient Population Addressed by CAR-T Clinical Trials
• Table 5.1: CAR-T Cell Target Antigens for Hematological Malignancies
• Table 5.2: CAR-T Target Antigens on Solid Tumors
• Table 6.1: Top 20 Companies in CAR-T Patent Landscape
• Table 6.2: TOP 20 Research Centers in CAR-T Patent Landscape
• Table 6.3: Top 20 CAR-T Inventors
• Table 6.4: Top Five CAR-T Patents with Maximum Patent Families
• Table 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship
• Table 6.6: Top Five Patents with Most Co-Applicants
• Table 6.7: Top Five Patents with Most Co-Applicants
• Table 7.1: Percent Target Distribution of World's CAR-T Clinical Trials
• Table 7.2: Targeted Biomarkers in the U.S. CAR-T Clinical Trials
• Table 7.3: Targeted Biomarkers in Chinese CAR-T Clinical Trials
• Table 7.4: Indications Addressed by CAR-T Clinical Trials in the U.S.
• Table 7.5: Indications Addressed by CAR-T Clinical Trials in China
• Table 7.6: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
• Table 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in China
• Table 7.8: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries
• Table 7.9: Clinical Trials of Fourth Generation/Next-Generation and Gene-Edited CAR-T
• Table 8.1: A Partial List of NIH Funding for CAR-T Research in 2021
• Table 9.1: Deal-Making in the CAR-T Therapy Sector
• Table 10.1: Sales Data for Kymriah and Yescarta, 2018 Full Year to 2020 Mid-Year
• Table 10.2: Efficacy, Safety and Composition of Approved CAR-T Products
• Table 10.3: Other Promising CAR-T Product Candidates
• Table 11.1: 2020 CAR-T Payment Disparities per Case in the U.S.
• Table 11.2: Reimbursement of CAR-T Cell Therapies in France
• Table 11.3: Reimbursement of CAR-T Cell Therapies in Germany
• Table 11.4: Reimbursement of CAR-T Cell Therapies in Italy
• Table 11.5: Reimbursement of CAR-T Cell Therapies in Spain
• Table 11.6: Reimbursement of CAR-T Cell Therapies in U.K.
• Table 12.1: Cost of Treating Blood Cancers
• Table 13.1: Estimated Global Market for CAR-T Therapy by Products, 2020-2028
• Table 13.2: Global Market for CAR-T Therapy by Geography, 2020-2028
• Table 13.3: Global Market for CAR-T Therapy by Indication, 2020-2028
• Table 13.4: Top Five CAR-T Companies by Marketed Products and Product Candidates
• Table 14.1: Atela's Pipeline of Product Candidates
• Table 14.2: Allogene's Product Pipeline
• Table 14.3: Anixa's Product Pipeline
• Table 14.4: Autolus' Pipeline of Clinical and Next Generation Programs
• Table 14.5: Bellicum Pharmaceutical's Product Candidates
• Table 14.6: CARsgen's Product Pipeline
• Table 14.7: Cartesian's Product Pipeline
• Table 14.8: Celyad's Product Pipeline
• Table 14.9: Creative Biolab's CAR Construction and Production Platform
• Table 14.10: CRISPR Therapeutics' Immuno-Oncology Programs
• Table 14.11: Cartesian's Product Pipeline
• Table 14.12: Eureka's CAR Products in Development for Juno Therapeutics
• Table 14.13: iPSC-Derived Product Candidates from Fate Therapeutics
• Table 14.14: Formula's Product Candidates
• Table 14.15: Gilead's Cell Therapy Programs in Oncology
• Table 14.16: iCell's Product Candidates
• Table 14.17: Juno's CAR-T Product Candidates
• Table 14.18: Kite's Pipeline of Product Candidates
• Table 14.19: Mustang Bio's Product Candidates
• Table 14.20: Nanjing's Autologous Product Pipeline for Hematologic Malignancies
• Table 14.21: Nanjing's Allogeneic Product Pipeline for Hematologic and Solid Cancers
• Table 14.22: Noil's Product Candidates for Solid Cancers
• Table 14.23: Oxford Biomedica's IP Enabled and Royalty Bearing Product Candidates
• Table 14.24: Poseida's Product Pipeline
• Table 14.25: Precigen's CAR-T Programs
• Table 14.26: Precision Bioscience's Off-the-Shelf Immunotherapy Pipeline
• Table 14.27: Sorrento's Immunotherapy Pipeline
• Table 14.28: TC Biopharm's Product Candidates
• Table 14.29: Tmunity's CAR-T Programs for Liquid and Solid Tumors
• Table 14.30: Wugen's Pipeline of Product Candidates
• Table 14.31: Xyphos' Product Pipeline
• Table 14.32: Ziopharm's CAR-T Product Candidates

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once infused into the patient, these CARs enable the T-cells to recognize and attach to an antigen on the cancer cell, leading to its destruction.

CAR-T Cell Therapy Market

Since the first historic CAR-T approvals in 2017, the following CAR T-cell therapies have reached commercialization:

• Kymriah (tisagenlecleucel)
• Yescarta (axicabtagene ciloleucel)
• Tecartus (brexucabtagene autoleucel)
• Breyanzi (lisocabtagene maraleucel)
• Abecma (idecabtagene vicleucel)

Additionally, JW Therapeutics achieved NMPA approval of Relma-cel (relmacabtagene autoleucel) in China. This is the first CAR-T product independently developed in China and approved as a Category 1 biologics product, as well as the sixth approved CAR-T product globally.

In 2012, there were only 12 CAR-T clinical trials. Today, this number had surged to over 1,200. Based on CAR-T products in the clinical pipeline, the number of approved CAR-T cell therapies is projected to reach double digits within the next five years and over a 100 by 2035.

This growth in the number of trials has been fueled by the unprecedented 90% remission rate shown in acute lymphoblastic leukemia (ALL) patients treated with Kymriah. From 60% to 70% of the patients treated in the earliest clinical trials are now in remission for more than nine years, which is an unprecedented accomplishment. The earliest approvals of Kymriah and Yescarta have been infused into an astounding half million patients worldwide.

These historic approvals demonstrate that the CAR-T market has arrived and is taking the biotech industry by storm. This has driven CAR-T funding to staggering new heights. At first the trend was subtle, but the tide has swelled as CAR-T start-ups have been richly funded by investors eager to get into this rapidly expanding area of regenerative medicine.

In aggregate, there has been an astonishing $100 billion of market capitalization from CAR-T companies in recent years. Financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute an astounding $2 billion.

M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead's acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma's acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.

This billion dollar market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

Recently released, this 254-page report reveals:

• CAR-T market size determinations with segmentation by product, geography, and indication, as well as future forecasts through 2027

• Detailed coverage of the approved CAR-T products, including regulatory approvals, pricing, reimbursement, and market penetration

• Clinical trial activity by type, geography, phase and sponsor

• Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and most cited patents

• CAR-T industry mergers and acquisitions, IPOs, and financing events

• Deal-making, strategic partnerships, and co-commercialization agreements within the CAR-T sector

• Little known market trends, future directions, and emerging opportunities

• Profiles of 62 leading CAR-T competitors composing the global marketplace

• And so much more

This 254-page global strategic report will position you to:

• 1. Capitalize on rapidly emerging trends

• 2. Optimize decision-making

• 3. Reduce company risk

• 4. Approach partners/investors for collaboration or funding

• 5. Implement an informed and advantageous business strategy in 2022

Although progressing at breakneck speed, developments within the field of CAR-T cell therapy are still early stage, positioning the market for remarkable expansion. Today is similar to the launch of the first chemotherapy treatments, when oncologists started treating patients with a single type of chemotherapy. Now, fifty years later, cancer patients are treated with over a hundred different chemotherapy agents. In the same way, we will soon have numerous CAR-T therapies available to treat liquid cancers, solid tumors, and autoimmune diseases, as well as inflammatory conditions.

With the competitive nature of this global market, you don't have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

TABLE OF CONTENTS

1. REPORT OVERVIEW

• 1.1. Statement of the Report
• 1.2. Executive Summary
• 1.3. Introduction

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

• 2.1. CAR-T Cell
• 2.2. Evolution of CAR-T Cell Development
  • 2.2.1. The CAR-T Cell Family
    • 2.2.1.1. First Generation CARs
    • 2.2.1.2. Second Generation CARs
    • 2.2.1.3. Third Generation CARs
    • 2.2.1.4. Fourth Generation CARs
• 2.3. Antigens Present on Hematological Cancer Cells
• 2.4. Tools for Inserting Receptor Genes into T Cells
• 2.5. Transforming T Cells into CAR-T Cells
• 2.6. The Five CAR-T Therapies Crossing the Finishing Line
• 2.7. Toxicities Associated with CAR-T Treatment
• 2.8. The Future of CAR-T Cell Therapy
  • 2.8.1. Transition from Liquid Cancers to Solid Tumors
  • 2.8.2. Reduction in the Length of Hospital Stay
  • 2.8.3. Discovery of New Target Antigens
  • 2.8.4. Shifting from Autologous to Allogeneic CAR-T Therapy
  • 2.8.5. CAR-T for the Masses
• 2.9. Advantages of CAR-T Therapy
• 2.10. Disadvantages of CAR-T Therapy
• 2.11. CAR-T Therapy Expansion in 2021 and Beyond
  • 2.11.1. Direct Competition among the Autologous CAR-T Therapies
  • 2.11.2. Allogeneic CD19 CAR-Ts: Current Status
  • 2.11.3. B-Cell Maturation Antigen (BCMA) CAR-Ts
  • 2.11.4. Other CAR-T Targets and Technologies

3. CAR-T CELL THERAPY: PRODUCT DEVELOPMENT

• 3.1. Current Status of CAR-T Therapy Products
• 3.2. Prospective CAR-T Product Candidates
• 3.3. Transformative Potential of CAR-T Therapy
• 3.4. Small Patient Population & Huge Clinical Trial Landscape

4. MANUFACTURE OF CAR-T CELLS

• 4.1. Automation in CAR-T Manufacturing
• 4.2. Operating Expenses in Autologous CAR-T Manufacturing
• 4.3. Operating Expenses in Allogeneic CAR-T Manufacturing

5. CAR-T TARGET ANTIGENS: A BRIEF OVERVIEW

• 5.1. CAR-T Target Antigens on Hematological Cancers
• 5.2. CAR-T Target Antigens on Solid Tumors
• 5.3. Common Antigens Targeted by CAR-T Cells
  • 5.3.1. Cluster of Differentiation 19 (CD19)
  • 5.3.2. Mesothelin
  • 5.3.3. B-Cell Maturation Agent (BCMA)
  • 5.3.4. GD2
  • 5.3.5. Glypican-3 (GPC3)
  • 5.3.6. Cluster Differentiation-22 (CD22)

6. CAR-T PATENT LANDSCAPE

• 6.1. Geographical Origin of CAR-T Patent Applications
• 6.2. Top Ten CAR-T Patent Jurisdictions
• 6.3. Affiliations of CAR-T Cell Patent Applicants
  • 6.3.1. Top 20 Companies in CAR-T Patent Landscape
  • 6.3.2. Top 20 Research Centers in CAR-T Patent Landscape
  • 6.3.3. Top 20 CAR-T Cell Inventors
  • 6.3.4. Top Five CAR-T Patents with Most Family Members
  • 6.3.5. Top Five CAR-T Patents with Most Inventors in Co-Authorship
  • 6.3.6. Top Five Patents with Most Co-Applicants
  • 6.3.7. Top Five CAR-T Patents with Most Citations Received

7. GLOBAL CAR-T CLINICAL TRIALS: AN OVERVIEW

• 7.1. CAR-T Targeted Biomarkers in Clinical Trials
  • 7.1.1. CAR-T Targeted Biomarkers in U.S. Clinical Trials
  • 7.1.2. CAR-T Targeted Biomarkers in Chinese Clinical Trials
  • 7.1.3. CAR-T Targeted Biomarkers in other Countries
• 7.2. CAR-T Targeted Indications in the U.S. Clinical Trials
• 7.3. Indications Addressed by CAR-T Clinical Trials in China
• 7.4. Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials
• 7.5. Phase of CAR-T Clinical Trials
• 7.6. CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
• 7.7. CAR-T Clinical Trial Sponsor Companies and Institutions in China
• 7.8. CAR-T Clinical Trial Sponsor Companies and Institutions in other Countries
• 7.9. Ongoing Clinical Trials with Improved CAR-T Constructs
  • 7.9.1. CAR-T with PD1Fc
  • 7.9.2. CAR-T with Truncated EGFR (EGFRt)
  • 7.9.3. CAR-T with IL7 and CCL19
  • 7.9.4. CAR-T with PD1/CD28 Switch-Receptor
  • 7.9.5. CAR-T with PD1 shRNA-expressing cassette
  • 7.9.6. CAR-T with CTLA-4/PD-1 Antibody
  • 7.9.7. CAR-T with PD-1 Antibodies
• 7.10. Geographic Distribution of CAR-T Clinical Trials
• 7.11. Distribution of CAR-T Clinical Trials by Type of CAR Generations
• 7.12. Distribution of CAR-T Clinical Trials by Type of ScFv Used
• 7.13. Distribution of CAR-T Clinical Trials by Type of Vectors Used

8. PUBLISHED SCIENTIFIC PAPERS & NIH GRANTS

• 8.1. Number of Published Papers
• 8.2. NIH Funding for CAR-T Research

9. DEALS IN CAR-T THERAPY SPACE

• 9.1. Most Recent CAR-T Deals
  • 9.1.1. Dr. Reddy's Laboratories/Shenzhen Pregene Biopharma
  • 9.1.2. Abbvie/Caribou Biosciences
  • 9.1.3. Gilead/Tango Therapeutics
  • 9.1.4. Kite/Teneobio
  • 9.1.5. Fate/Janssen
  • 9.1.6. Juno/Oxford Biomedica
  • 9.1.7. Allogene/MaxCyte
  • 9.1.8. Applied DNA Sciences, Inc.
  • 9.1.9. Cellectis/Servier
  • 9.1.10. Cell Therapies, Pvt. Ltd
  • 9.1.11. Astellas/Adaptimmune
  • 9.1.12. Astellas/Xyphos
  • 9.1.13. Carisma Therapeutics, Inc./NYU Langone Health

10. MARKETED CAR-T PRODUCTS

• 10.1. Kymriah (Tisagenlecleucel)
  • 10.1.1. Mechanism of Action
  • 10.1.2. Dosing
  • 10.1.3. Safety and Efficacy of Kymriah
  • 10.1.4. Kymriah's Cost
  • 10.1.5. Current Sales of Kymriah
• 10.2. Yescarta (Axicabtagene ciloleucel)
  • 10.2.1. Mechanism of Action
  • 10.2.3. Dosing
  • 10.2.4. Safety and Efficacy of Yescarta
  • 10.2.5. Manufacturing Network
  • 10.2.6. Current sales of Yescarta
  • 10.2.7. Sales of Kymriah and Yescarta: A Comparison
• 10.3. Tecartus (Brexucabtagene autoleucel)
  • 10.3.1. Mechanism of Action
  • 10.3.2. Dosing
  • 10.3.3. Safety and Efficacy of Tecartus
• 10.4. Breyanzi (Lisocabtagene maraleucel)
  • 10.4.1. Mechanism of Action
  • 10.4.2. Dosing
  • 10.4.3. Safety and Efficacy of Breyanzi
  • 10.4.4. Efficacy, Safety and Composition of Approved CAR-T Products
• 10.5. Abecma (Idecabtagene vicleucel/Ide-Cel)
  • 10.5.1. Health Canada's Conditional Approval
  • 10.5.2. EMA's Conditional Marketing Authorization
  • 10.5.3. Selected BCMA-Targeted Multiple Myeloma Therapies
• 10.6. Other Promising CAR-T Product Candidates
  • 10.6.1. ALLO-501
  • 10.6.2. CTX110
  • 10.6.3. UCART19
  • 10.6.3. AUTO1
  • 10.6.4. JCARH125
  • 10.6.5. LCAR-B38M
  • 10.6.6. PBCAR20A
  • 10.6.7. UCART123
  • 10.6.8. PRGN-3006
  • 10.6.9. UCART22
  • 10.6.10. UCARTCS1

11. REIMBURSEMENT FOR CAR-T THERAPIES

• 11.1. Hospital Reimbursement in the U.S. for CAR-T Therapy
• 11.2. Outcomes-Based Reimbursement for CAR-T Therapies in EU5 Countries
  • 11.2.1. France
  • 11.2.2. Germany
  • 11.2.3. Italy
  • 11.2.4. Spain
  • 11.2.5. U.K.

12. BLOOD CANCERS: TECHNOLOGIES AND TREATMENTS

• 12.1. Lymphoma
  • 12.1.1. Hodgkin Lymphoma (HL)
  • 12.1.2. Non-Hodgkin Lymphoma (NHL)
    • 12.1.2.1. Diffuse Large B Cell Lymphoma (DLBCL)
    • 12.1.2.2. Follicular Lymphoma (FL)
• 12.2. Leukemia
  • 12.2.1. Types of Leukemia
    • 12.2.1.1. Acute Myeloid Leukemia (AML)
    • 12.2.1.2. Acute Lymphoblastic Leukemia (ALL)
    • 12.2.1.3. Chronic Myeloid Leukemia (CML)
    • 12.2.1.4. Chronic Lymphocytic Leukemia (CLL)
• 12.3. Multiple Myeloma (MM)
• 12.4. Treatment Options for Blood Cancers
  • 12.4.1. Chemotherapy
  • 12.4.2. Radiation Therapy
  • 12.4.3. Targeted Therapy
  • 12.4.4. Stem Cell Transplantation
  • 12.4.5. Immunotherapy
    • 12.4.5.1. Monoclonal Antibodies (mAbs)
    • 12.4.5.2. Immune Check-point Inhibitors
    • 12.4.5.3. Adoptive Cell Transfer Therapy/T-Cell Transfer Therapy
• 12.5. The Staggering Cost of Cancer Therapy

13. CAR-T CELL THERAPY MARKET ANALYSIS

• 13.1. Global Market for CAR-T Cell Therapy by Product
• 13.2. Global Market for CAR-T Therapy by Geography
• 13.3. Global Market for CAR-T Therapy by Indication
• 13.4. Companies at the Forefront of CAR-T Market
• 13.5. Barriers and Strategies for Success in CAR-T 2.0 Market Place
  • 13.5.1. Barriers to CAR-T 2.0 Commercial Success
    • 13.5.1.1. Capacity constraints
    • 13.5.1.2. Competition among Manufacturers
    • 13.5.1.3. Competition from other Treatments
  • 13.5.2. Market Development Strategies for CAR-T 2.0
    • 13.5.2.1. Effective Physician Education
    • 13.5.2.2. Logistical Excellence
    • 13.5.2.3. Evidence Generation

14. CAR-T COMPANY PROFILES

• 14.1. Aleta BioTherapeutics
  • 14.1.1. Atela's Pipeline
• 14.2. Allogene Therapeutics
  • 14.2.1. AlloCAR-T Therapy
• 14.3. Anixa Biosciences, Inc.
• 14.4. Arcellx, Inc.
  • 14.4.1. Technology
  • 14.4.2. CART-ddBCMA
• 14.5. Atara Biotherapeutics
  • 14.5.1. Technology
  • 14.5.2. Next-Generation CAR-T
• 14.6. Autolus Therapeutics, plc
• 14.7. Bellicum Pharmaceuticals, Inc.
  • 14.7.1. GoCAR Technology
  • 14.7.2. Bellicum's Pipeline
• 14.8. BioNTech
  • 14.8.1. Collaborators
  • 14.8.2. Services
  • 14.8.3. Engineered Cell Therapies
  • 14.8.4. CAR-T Programs
    • 14.8.4.1. BNT211
    • 14.8.4.2. BNT212
• 14.9. bluebird bio
  • 14.9.1. CAR-T Collaborations
    • 14.9.1.1. Collaboration with Celgene
    • 14.9.1.2. Collaboration with Inhibrx
    • 14.9.1.3. Collaboration with TC BioPharm
• 14.10. Cabaletta Bio
  • 14.10.1. CAAR Technology
  • 14.10.2. Cabaletta's Pipeline
• 14.11. Carina Biotech
  • 14.11.1. New CAR-T Cells
  • 14.11.2. CAR-T Access Technologies
    • 14.11.2.1. Chemokine Receptor Mediation
    • 14.11.2.2. Gel Formulation to Deliver CAR-T Cells
• 14.12. CARsgen Therapeutics
• 14.13. Cartesian Therapeutics, Inc.
  • 14.13.1. Cartesian's Approach
• 14.14. CARTherics
  • 14.14.1. Technology
• 14.15. Celgene Corporation
  • 14.15.1. Lisocabtagene maraleucel (liso-cel)
• 14.16. Cellectis
  • 14.16.1. Universal Chimeric Antigen Receptor T-Cells (UCARTs)
    • 14.16.1.1. UCART 123
    • 14.16.1.2. UCART22
    • 14.16.1.3. UCARTCS1
    • 14.16.1.4. UCART19
    • 14.16.1.5. ALLO-501
    • 14.16.1.6. ALLO-715
• 14.17. Celularity, Inc.
  • 14.17.1. P CAR-T
• 14.18. Celyad Oncology
  • 14.18.1. TIM Technology
  • 14.18.2. shRNA Technology
• 14.19. Creative Biolabs
  • 14.19.1. CAR Construction and Production Platform
• 14.20. CRISPR Therapeutics
  • 14.20.1. CRISPR/Cas9 Immuno-Oncology Cell Therapy
• 14.21. CytoSeek
  • 14.21.1. Technology
  • 14.21.2. Pipeline
• 14.22. Cytovia Therapeutics
• 14.23. DiaCarta, Inc.
  • 14.23.1. Personalized CAR-T Immunotherapy Platform
• 14.24. Empirica Therapeutics
  • 14.24.1. Technology
• 14.25. Eureka Therapeutics, Inc.
• 14.26. EXUMA Biotech Corp.
  • 14.26.1. Logic Gate CAR-T Technology
  • 14.26.2. Same-Day CAR-T Therapy
• 14.27. Fate Therapeutics, Inc.
• 14.28. Formula Pharmaceuticals, Inc.
  • 14.28.1. Technology
• 14.29. GEMoaB
  • 14.29.1. UniCAR Platform
  • 14.29.2. RevCAR Platform
  • 14.29.3. GEMoaB's Pipeline
• 14.30. Gilead Sciences, Inc.
  • 14.30.1. TECARTUS (Brexucabtagene autoleucel)
  • 14.30.2. Yescarta (Axicabtagene ciloleucel)
  • 14.30.3. Cell Therapy
• 14.31. Gracell Biotechnologies
  • 14.31.1. Dual CAR
  • 14.31.2. FasTCAR
  • 14.31.3. TrUCAR
• 14.32. iCell Gene Therapeutics
  • 14.32.1. iCell Platforms
    • 14.32.1.1. CARvac
    • 14.32.1.2. Non Gene Edited Universal CARs
    • 14.32.1.3. C-TPS1
    • 14.32.1.4. T-Cell Targeted CARs
    • 14.32.1.5. Compound CARs
• 14.33. Janssen Biotech, Inc.
  • 14.33.1. JNJ-4528
• 14.34. Juno Therapeutics
• 14.35. JW Therapeutics, Co., Ltd.
  • 14.35.1. Relmacabtagene autoleucel (Relma-cel)
• 14.36. Kite Pharma, Inc.
  • 14.36.1. Kite's Technologies (CAR-T & TCR)
  • 14.36.2. Kite's Therapies
    • 14.36.2.1. Yescarta (Axicabtagene ciloleucel)
    • 14.36.2.2. Tecartus (Brexucabtagene autoleucel)
• 14.37. Kyverna Therapeutics
  • 14.37.1. SynNotch CAR-T Platform
• 14.38. Lyell Immunopharma, Inc.
  • 14.38.1. Technologies
  • 14.38.2. Gen-R Technology
  • 14.38.3. Epi-R Technology
• 14.39. MaxCyte, Inc.
  • 14.39.1. CARMA Cell Therapies
  • 14.39.2. Flow Electroporation Technology
• 14.40. Minerva Biotechnologies Corporation
  • 14.40.1. HuMNC2-CAR44
• 14.41. Mnemo Therapeutics
  • 14.41.1. Mnemo's Approach
• 14.42. Mustang Bio, Inc.
• 14.43. Nanjing Legend Biotechnology Co., Ltd.
  • 14.43.1. LCAR-B38M/JNJ-4528
• 14.44. Noile-Immune Biotech
• 14.45. Novartis International, AG
  • 14.45.1. Kymriah (Tisagenlecleucel)
• 14.46. Oxford Biomedica plc
• 14.47. PeproMene Bio, Inc.
  • 14.47.1. BAFF-R CAR-T Cells
• 14.48. Poseida Therapeutics, Inc.
  • 14.48.1. PiggyBac DNA Modification System
  • 14.48.2. Autologous & Allogeneic Programs
    • 14.48.2.1. P-BCMA-101
    • 14.48.2.2. P-PSMA-101
    • 14.48.2.3. P-BCMA-ALLO1
    • 14.48.2.4. P-MUC1C-ALLO1
    • 14.48.2.5. P-PSMA-ALLO1
• 14.49. Precigen, Inc.
• 14.50. Precision Biosciences
• 14.51. Prescient Therapeutics
  • 14.51.1. OmniCAR Technology
• 14.52. ProMab Biotechnologies, Inc.
  • 14.52.1. Custom CAR-T Cell Development
• 14.53. Protheragen
  • 14.53.1. PR-18-01
• 14.54. Sorrento Therapeutics, Inc.
• 14.55. Synthekine
  • 14.55.1. STK-009 + SYNCAR-001
• 14.56. TC Biopharm
  • 14.56.1. Co-Stim CAR-T
• 14.57. T-CURX
  • 14.57.1. CARAMBA
• 14.58. Tessa Therapeutics, Pvt. Ltd.
  • 14.58.1. CD30 CAR-T Cells
  • 14.58.2. Allogeneic CD30-CAR EBVSTs
• 14.59. Tmunity Therapeutics, Inc.
• 14.60. Wugen
• 14.61. Xyphos Biosciences, Inc.
  • 14.61.1. Xyphos' Strategy
• 14.62. Ziopharm Oncology, Inc.
  • 14.62.1. Non-Viral CAR-T Therapy

APPENDIX

• Appendix 1: Medical Centers offering CAR-T Therapies in the U.S.